ubiquinol-cytochrome c reductase binding protein pseudogene 2Genealiases: []
Q-omics provides the consensus-scored UQCRBP2 profile across patient tissues and cancer cell-line models. UQCRBP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, UQCRBP2 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, UQCRBP2 RNA expression shows 6,766 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, BRCA, and STAD as cancer lineages where UQCRBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UQCRBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UQCRBP2 survival associations across molecular data types. UQCRBP2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UQCRBP2 RNA expression–survival associations across cancer types. High UQCRBP2 expression shows unfavorable associations in UCS, UCEC, LUAD and COAD, but favorable associations in BLCA and LUSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for UQCRBP2 RNA expression.
This table summarizes UQCRBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for UQCRBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UQCRBP2 shows higher tumor expression in BRCA, KIRP, LUSC, LUAD, KIRC and PRAD. The BRCA box plot shows higher UQCRBP2 RNA expression in tumor versus normal tissue (log2 FC = +0.204, t-test p < 0.001).
This table shows molecular features associated with UQCRBP2 in patient tissues and cancer cell lines. In patient samples, UQCRBP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
